Ítem
Solo Metadatos

Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field

Mostrar el registro sencillo de la publicación
dc.creatorMantilla Galindo A.spa
dc.creatorOcampo M.spa
dc.creatorPatarroyo M.A.spa
dc.date.accessioned2020-05-26T00:08:02Z
dc.date.available2020-05-26T00:08:02Z
dc.date.created2019spa
dc.description.abstractIntroduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages; however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria, and its efficacy decreases with a host’s age. Areas covered: Following a comprehensive search of the available literature, this review describes some of the most frequently used animal models, the most frequently used methods for evaluating efficacy in animal models and some in vitro strategies as alternatives for evaluating vaccines. Expert opinion: Identifying the animal models used up to now for evaluating vaccines during their development stages, their characteristics and limitations, as well as knowledge regarding strategies for evaluating promising vaccine candidate efficacy, will ensure more efficient, reliable and reproducible pre-clinical trials. Although much of the knowledge accrued to date concerning vaccine effectiveness against tuberculosis has been based on animal models, it is clear that large questions still need to be resolved and that extrapolation of such efficacy to humans has yet to be achieved. © 2019, © 2019 Informa UK Limited, trading as Taylor and Francis Group.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1080/14760584.2019.1583558
dc.identifier.issn14760584
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24049
dc.language.isoengspa
dc.publisherTaylor and Francis Ltdspa
dc.relation.citationEndPage377
dc.relation.citationIssueNo. 4
dc.relation.citationStartPage365
dc.relation.citationTitleExpert Review of Vaccines
dc.relation.citationVolumeVol. 18
dc.relation.ispartofExpert Review of Vaccines, ISSN:14760584, Vol.18, No.4 (2019); pp. 365-377spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85063743028&doi=10.1080%2f14760584.2019.1583558&partnerID=40&md5=14410216e9e2b4040a334f2b06766fdbspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBCG vaccinespa
dc.subject.keywordCytokinespa
dc.subject.keywordAnimal modelspa
dc.subject.keywordBacterial loadspa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordExperimental modelspa
dc.subject.keywordGuinea pig modelspa
dc.subject.keywordHumanspa
dc.subject.keywordIn vitro studyspa
dc.subject.keywordNonhumanspa
dc.subject.keywordPrimate modelspa
dc.subject.keywordPriority journalspa
dc.subject.keywordReviewspa
dc.subject.keywordSurvivalspa
dc.subject.keywordTuberculosisspa
dc.subject.keywordZebra fishspa
dc.subject.keywordAnimal modelspa
dc.subject.keywordMycobacterium sppspa
dc.subject.keywordTuberculosisspa
dc.subject.keywordVaccinespa
dc.titleExperimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the fieldspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos